Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications
From episodic assessment to comprehensive assessment: integrating real-world monitoring in relapsed/refractory multiple myeloma.
Journal: Expert review of hematology
Published: May 27, 2026
The ClinicalTrials.gov Landscape of Multiple Myeloma Clinical Trials: A 20-Year Analysis of Geographic Distribution and Growth Patterns: USMIRC Analysis.
Journal: Current oncology (Toronto, Ont.)
Published: May 05, 2026
Evaluation of Real-World Studies on Management of Relapsed Multiple Myeloma After BCMA-Directed Therapy Failure from U.S. Academic Centers and USMIRC.
Journal: Current oncology (Toronto, Ont.)
Published: March 17, 2026
A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment-USMIRC Group.
Journal: Cancers
Published: December 12, 2025
Genomic Determinants and Clinical Outcomes of Second Primary Hematological Malignancies in Patients with B-cell Cancers.
Journal: Transplantation and cellular therapy
Published: October 28, 2025
Teclistamab Dosing Strategies in Relapsed/Refractory Myeloma: A Real-World Comparison of Weekly and Biweekly Versus Fixed Intervals.
Journal: Cancers
Published: September 19, 2025
BCMA-Directed CAR T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma and Renal Impairment.
Journal: Current oncology (Toronto, Ont.)
Published: September 15, 2025
Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists.
Journal: Blood reviews
Published: July 25, 2025
Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial.
Journal: Clinical lymphoma, myeloma & leukemia
Published: July 06, 2025
Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma.
Journal: Advances in therapy
Published: May 08, 2025
Last Updated: 09/26/2026